Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough.

Cancer cell - 11 Jan 2021

Gerlinger Marco

Abstract excerpt

Abundant neoantigens are considered responsible for the immunotherapy sensitivity of mismatch repair-deficient (MMRd) cancers. In this issue of Cancer Cell, two papers show that MLH1 mismatch repair gene loss promotes cGAS-STING activation, interferon secretion, and T cell priming. This may be essential for the high immunotherapy sensitivity in MMRd cancer.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA
Share to DNA Mismatch Repair
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 33434509
DOI: 10.1016/j.ccell.2020.12.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough.PMID 33434509Read ↗

DNA mismatch repair in cancer immunotherapySemantic proximity Read ↗

The role of DNA mismatch repair in immunotherapy of human cancer.Semantic proximity Read ↗

DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining ImmunotherapySemantic proximity Read ↗

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal CancersSemantic proximity Read ↗

Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity.Semantic proximity Read ↗

Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.Semantic proximity Read ↗

Mismatch repair deficiency is not sufficient to increase tumor immunogenicitySemantic proximity Read ↗

cGAS-STING–mediated DNA sensing maintains CD8 + T cell stemness and promotes antitumor T cell therapySemantic proximity Read ↗

Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of CancerSemantic proximity Read ↗

Mismatch repair deficiency reshapes glioblastoma through immune suppression rather than hypermutation.Semantic proximity Read ↗

Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair-deficient tumors.Semantic proximity Read ↗

Treg-derived TGF-β1 dampens cGAS-STING signaling to downregulate the expression of class I MHC complex in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.